IONS Q4 2022 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$152M-65.5% YoY

Gross Profit

$148M97.6% margin

Operating Income

-$208M-137.0% margin

Net Income

-$52M-34.5% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-4.9%

Cash Flow

Operating Cash Flow

-$200M

Free Cash Flow

-$205M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$2.0B

Stockholders' Equity

$573M

Cash & Equivalents

$276M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$152M	$440M	-65.5%
Gross Profit	$148M	$438M	-66.1%
Operating Income	-$208M	$221M	-194.3%
Net Income	-$52M	$225M	-123.3%

Revenue Segments

Commercial

$80M26%

Research and Development Revenue

$71M24%

Spinraza Royalties

$67M22%

Collaborative Agreement Revenue

$50M16%

Eplontersen Joint Development Revenue

$21M7%

Product

$8M2%

Licensing and Other Royalties

$6M2%